Evidence map›Paper›PMID 27184625›Full record

GuidelineBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT.

Zachariah DeFilipp, Rafael F Duarte, John A Snowden, Navneet S Majhail, Diana M Greenfield, José López Miranda, Mutlu Arat, K Scott Baker, Linda J Burns, Christine N Duncan and 29 more

Open access · greenAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Pediatric Hematopoietic Cell Transplant Patients Who Survive Critical Illness Frequently Have Significant but Recoverable Decline in Functional Status.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 8 countries.

Zachariah DeFilippDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Rafael F DuarteHospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
John A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and Department of Oncology & Metabolism, University of Sheffield, Sheffield, United Kingdom.
Navneet S MajhailDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.
Diana M GreenfieldSpecialized Cancer Services, Sheffield Teaching Hospital NHS Foundation Trust, Shefflied, United Kingdom.
José López MirandaDepartment of Medicine, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research at Cordoba (IMIBIC), University of Cordoba, CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.
Mutlu AratFlorence Nightingale Sisli Hospital, Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Linda J BurnsNational Marrow Donor Program, University of Minnesota, Minneapolis, Minnesota.
Christine N DuncanPediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Boston, Massachusetts.
Maria GilleeceLeeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Gregory A HaleAll Children's Hospital, John Hopkins Medicine, St. Petersburg, Florida.
Mehdi HamadaniCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Betty K HamiltonDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.
William J HoganDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Jack W HsuDivision of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, Florida.
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Maria Teresa Lupo-StanghelliniHematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
Adriana K MaloneDivision of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Philip McCarthyRoswell Park Cancer Institute, BMT Program, Department of Medicine, Buffalo, New York.
Mohamad MohtyUniversity Pierre & Marie Curie, Paris, France; Hopital Saint-Antoine, AP-HP, Paris, France; INSERM UMRs 938, Paris, France.
Maxim NorkinDivision of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, Florida.
Pamela PaplhamRoswell Park Cancer Institute, BMT Program, Department of Medicine, Buffalo, New York.
Muthalagu RamanathanDepartment Hematology, Oncology and Bone Marrow Transplant, UMass Memorial Medical Center, Worcester, Massachusetts.
John M RichartSaint Louis University, Department of Internal Medicine, Division of Hematology and Medical Oncology, St. Louis, Missouri.
Nina SaloojaHammersmith Hospital, London, United Kingdom.
Harry C SchoutenMaastricht University Medical Center, Maastricht, The Netherlands.
Helene SchoemansDepartment of Hematology, University Hospital Leuven and KU Leuven, Leuven, Belgium.
Adriana SeberHospital Samaritano, Sao Paulo, Brazil; Associação da Medula Ossea - AMEO, Sao Paulo, Brazil.
Amir SteinbergDivision of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Baldeep M WirkDepartment of Internal Medicine, Stony Brook University Medical Center, Stony Brook, New York.
William A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina.
Minoo BattiwallaHematology Branch, National Institutes of Health, Bethesda, Maryland.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Bronwen E ShawCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: bshaw@doctors.org.uk.
CIBMTR Late Effects and Quality of Life Working Committee
EBMT Complications and Quality of Life Working Party
Cleveland Clinic · USFred Hutch Cancer Center · USIcahn School of Medicine at Mount Sinai · USMedical College of Wisconsin · USRoswell Park Comprehensive Cancer Center · USSheffield Teaching Hospitals NHS Foundation Trust · GBUniversity of Florida · USBaylor College of Medicine · USBrazilian Medical Association · BRDana-Farber Cancer Institute · USEmory University · USHammersmith Hospital · GBHospital Universitario Puerta de Hierro Majadahonda · ESInserm · FRInstituto de Salud Carlos III · ESIstanbul Florence Nightingale Hospital · TRJohns Hopkins University · USKU Leuven · BELeeds Teaching Hospitals NHS Trust · GBMaastricht University · NL

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

Indexed as

Cardiovascular DiseasesHematopoietic Stem Cell TransplantationHumansMetabolic SyndromeRisk FactorsTransplantation, HomologousCardiovascular diseaseHematopoietic cell transplantationLate effectsMetabolic syndromeSurvivorship

Identifiers

PMID27184625
PMCPMC4949101
OpenAlexW2378914995

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.